All In Biotech

Drug Trial Radar · NCT00660894

Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression

Last checked: Nov 19, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,535 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,535

Actual

Start

Apr 2008

Primary completion

Jun 2012

Study completion Jul 2015

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as tegafur-uracil, leucovorin, and S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving tegafur-uracil together with leucovorin is more effective than giving S-1 in treating patients with stage III colon cancer. PURPOSE: This randomized phase III trial is studying giving tegafur-uracil together with leucovorin to see how well it works compared with giving S-1 in treating patients with stage III colon cancer that has been completely removed by surgery.

Conditions

  • Colorectal Cancer

Interventions

  • folinate calciumDrug

  • tegafur-uracilDrug

  • tegafur-gimeracil-oteracil potassiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tokyo Medical and Dental University

    Tokyo, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.